摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 6-bromo-8-fluoro-4-oxo-spiro[chromane-2,4'-piperidine]-1'-carboxylate | 1291076-47-5

中文名称
——
中文别名
——
英文名称
tert-butyl 6-bromo-8-fluoro-4-oxo-spiro[chromane-2,4'-piperidine]-1'-carboxylate
英文别名
8-fluoro-6-bromo-4-oxo-spiro[chromane-2,4'-piperidine]-1'-carboxylic acid tert-butyl ester;tert-butyl 6-bromo-8-fluoro-4-oxospiro[3H-chromene-2,4'-piperidine]-1'-carboxylate
tert-butyl 6-bromo-8-fluoro-4-oxo-spiro[chromane-2,4'-piperidine]-1'-carboxylate化学式
CAS
1291076-47-5
化学式
C18H21BrFNO4
mdl
——
分子量
414.271
InChiKey
ITVMZOJURATMTN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    504.1±50.0 °C(Predicted)
  • 密度:
    1.48±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    25
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    55.8
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tert-butyl 6-bromo-8-fluoro-4-oxo-spiro[chromane-2,4'-piperidine]-1'-carboxylate三乙基硅烷 、 sodium tetrahydroborate 、 四(三苯基膦)钯乙醇 、 sodium carbonate 、 三氟乙酸 作用下, 以 1,4-二氧六环二氯甲烷 为溶剂, 反应 163.5h, 生成 tert-butyl 8-fluoro-6-(8-methyl-7-quinolyl)spiro[chromane-2,4'-piperidine]-1'-carboxylate
    参考文献:
    名称:
    [EN] SPIROPIPERIDINE DERIVATIVES
    [FR] DÉRIVÉS DE SPIROPIPÉRIDINE
    摘要:
    本文所述的是根据式I的螺哌啶化合物,它们已显示出作为脂肪酸合成酶抑制剂的活性。本文还描述了含有所述螺哌啶化合物的药物组合物,以及通过施用本文所述的一种或多种化合物或药物制剂来治疗由脂肪酸合成酶介导的疾病的方法。本文还描述了合成所述化合物的方法,包括所述螺哌啶化合物及其在那些合成中有用的合成中间体。
    公开号:
    WO2018112204A1
  • 作为产物:
    描述:
    1-(5-溴-3-氟-2-羟基苯基)乙酮N-叔丁氧羰基-4-哌啶酮四氢吡咯 作用下, 以 甲醇 为溶剂, 反应 17.0h, 以77%的产率得到tert-butyl 6-bromo-8-fluoro-4-oxo-spiro[chromane-2,4'-piperidine]-1'-carboxylate
    参考文献:
    名称:
    [EN] SPIROPIPERIDINE DERIVATIVES
    [FR] DÉRIVÉS DE SPIROPIPÉRIDINE
    摘要:
    本文所述的是根据式I的螺哌啶化合物,它们已显示出作为脂肪酸合成酶抑制剂的活性。本文还描述了含有所述螺哌啶化合物的药物组合物,以及通过施用本文所述的一种或多种化合物或药物制剂来治疗由脂肪酸合成酶介导的疾病的方法。本文还描述了合成所述化合物的方法,包括所述螺哌啶化合物及其在那些合成中有用的合成中间体。
    公开号:
    WO2018112204A1
点击查看最新优质反应信息

文献信息

  • Spirocyclic derivatives as histone deacetylase inhibitors
    申请人:DAC S.r.l.
    公开号:EP2311840A1
    公开(公告)日:2011-04-20
    This invention is related to new histone deacetylase inhibitors according to the general formula (I), wherein: is a single or a double bond; m and n are independently zero or an integer from 1 to 4; p is zero or an integer from 1 to 3, with the proviso that when p is zero, n and m cannot be both 1; R is hydrogen; C1-C6 alkyl, optionally substituted by cycloalkyl, aryl or by heteroaryl; (CO)R2; (SO2)R3; cycloalkyl; aryl; or heteroaryl; R1 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy; X is CH2, oxygen or NR4; Y is CHR5 or NR6; Z is CR7R8 or C=R9; and R2, R3, R4, R5, R6, R7, R9, and R9 are as further defined in the specification; and pharmaceutical acceptable salts thereof.
    这项发明涉及新的组蛋白去乙酰化酶抑制剂,其通式为(I),其中:是一个单键或双键;m和n分别为0或1至4的整数;p为0或1至3的整数,但当p为0时,n和m不能同时为1;R为氢;C1-C6烷基,可选地被环烷基、芳基或杂环烷基取代;(CO)R2;(SO2)R3;环烷基;芳基;或杂环烷基;R1为卤素,C1-C6烷基,C1-C6卤代烷基,C1-C6烷氧基,C1-C6卤代烷氧基;X为CH2、氧或NR4;Y为CHR5或NR6;Z为CR7R8或C=R9;以及规范中进一步定义的R2、R3、R4、R5、R6、R7、R9和R9;以及其药用可接受的盐。
  • SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
    申请人:Varasi Mario
    公开号:US20120258949A1
    公开(公告)日:2012-10-11
    This invention is related to new histone deacetylase inhibitors according to the general formula (I), wherein: m and n are independently zero or an integer from 1 to 4; p is zero or an integer from 1 to 3, with the proviso that when p is zero, n and m cannot be both 1; R is hydrogen; C 1 -C 6 alkyl, optionally substituted by C 3 -C 8 cycloalkyl, C 6 -C 10 aryl or hetero(C 2 -C 9 )aryl; (CO)R 2 ; (SO 2 )R 3 ; C 3 -C 8 cycloalkyl; C 6 -C 10 aryl; or hetero(C 2 -C 9 )aryl; R 1 is halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy; Y is CH 2 or NR 4 ; Z is C═R 5 ; and R 2 , R 3 , R 4 , and R 5 are as further defined in the specification; and pharmaceutical acceptable salts thereof.
    本发明涉及一种新的组蛋白去乙酰化酶抑制剂,其通式为(I),其中:m和n独立地为0或1到4的整数;p为0或1到3的整数,但当p为0时,n和m不能同时为1;R为氢;C1-C6烷基,可选地被C3-C8环烷基,C6-C10芳基或杂环(C2-C9)芳基取代;(CO)R2;(SO2)R3;C3-C8环烷基;C6-C10芳基;或杂环(C2-C9)芳基;R1为卤素,C1-C6烷基,C1-C6卤代烷基,C1-C6烷氧基,C1-C6卤代烷氧基;Y为CH2或NR4;Z为C═R5;R2、R3、R4和R5如规范中进一步定义;以及其药学上可接受的盐。
  • Spiropiperidine derivatives
    申请人:89BIO LTD
    公开号:US11046707B2
    公开(公告)日:2021-06-29
    Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.
    本文描述了根据式 I 的螺环哌啶化合物,这些化合物作为脂肪酸合成酶抑制剂已被证明具有活性。本文还描述了含有所述螺哌啶化合物的药物组合物,以及通过施用一种或多种本文所述化合物或药物制剂治疗由脂肪酸合成酶介导的疾病的方法。本文还描述了合成所述化合物的方法,包括所述螺哌啶化合物和在这些合成中有用的合成中间体。
  • [EN] SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] DÉRIVÉS SPIROCYCLIQUES FORMANT INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
    申请人:DAC SRL
    公开号:WO2011045265A3
    公开(公告)日:2011-06-30
  • SPIROPIPERIDINE DERIVATIVES
    申请人:89BIO LTD
    公开号:US20200031840A1
    公开(公告)日:2020-01-30
    Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.
查看更多